Pharmaceutical

MSD makes licence agreement with Hengrui Pharma for Lp(a) inhibitor

MSD has entered an exclusive licence agreement with Hengrui Pharma for the oral small molecule Lp(a) inhibitor, HRS-5346.

Mar 27, 2025 - 06:00
MSD makes licence agreement with Hengrui Pharma for Lp(a) inhibitor
MSD has entered an exclusive licence agreement with Hengrui Pharma for the oral small molecule Lp(a) inhibitor, HRS-5346.
Read the original article

Tags:

Previous Article

Character Biosciences gains $93m for precision eye disease therapies

Next Article

Immunovant will not pursue approval for the autoimmune medication

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Developing high-potent APIs: The necessary steps to follow

Developing high-potent APIs: The necessary steps to follow

Aug 7, 2024

BR-6002 by Boryung Pharmaceutical for Duodenal Ulcer: L...

Aug 28, 2023

Here’s a new data point for cancer patients to consider: ‘time toxicity’

Here’s a new data point for cancer patients to consider...

Apr 11, 2023